Clinical trial
A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel (Stargazer)
NCT06224413 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel (Stargazer)
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 27, 2024
- Completion date
- December 30, 2047
- Enrollment
- 120 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cerebral adrenoleukodystrophy (cald)